Skip to main content

Advertisement

SpringerLink
Log in

CD109 is a potential target for triple-negative breast cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of this study is to explore the expression of CD109 in breast cancer stem cells and the relationship between CD109 protein and clinicopathological characteristics of breast cancer. CD44+/CD24− tumor cells (CSCs) were selected by flow cytometry. The protein expression of CD109 was analyzed by immunohistochemistry staining, and the relationship between CD109 and clinicopathological parameters of breast cancer was determined. CD109 positively regulated the proliferation of breast CSCs in vitro, and CD109 protein expression was significantly higher in triple-negative breast cancer (TNBC) compared to non-TNBC (63.78 vs. 3.71 %, P = 0.001). Moreover, CD109 protein expression was related to the histological grade of breast cancer (P = 0.015), whereas age (P = 0.731), tumor size (P = 0.995), clinical stage (P = 0.644), and lymph node metastasis (P = 0.924) were not. In the logistic regression model, histological grade (P = 0.001) and molecular type (P = 0.001) were significantly related to CD109 expression. The patients with high expression of CD109 protein had significantly poorer postoperative disease-specific survival than those with no or low expression of CD109 protein (P = 0.001). In the Cox regression, CD109 was an independent prognostic factor (P = 0.001). CD109 is highly expressed in TNBC and is a potential biomarker for the initiation, progression, and differentiation of breast cancer tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.

    Article  Google Scholar 

  2. Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10:R10.

    Article  Google Scholar 

  3. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217–26.

    Article  CAS  Google Scholar 

  4. Gao N, Xu H, Liu C, Xu H, Chen G, Wang X, Li Y, Wang Y. Nestin: predicting specific survival factors for breast cancer. Tumour Biol. 2014

  5. Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.

    Article  CAS  Google Scholar 

  6. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253(6):1165–71.

    Article  Google Scholar 

  7. Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 2013;8(12):e84187.

    Article  Google Scholar 

  8. Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, et al. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One. 2013;8(9):e74345.

    Article  CAS  Google Scholar 

  9. COTZIAS GC, BORG DC, SELLECK B. Virtual absence of turnover in cadmium metabolism: Cd109 studies in the mouse. Am J Physiol. 1961;201:927–30.

    Article  CAS  Google Scholar 

  10. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2010;124(1):27–38.

    Article  CAS  Google Scholar 

  11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.

    Article  CAS  Google Scholar 

  12. Ozbay PÖ, Ekinci T, Yiǧit S, Yavuzcan A, Uysal S, Soylu F, et al. Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma. Oncol Targets Ther. 2013;6:621–7.

    Google Scholar 

  13. Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012;14(3):R144.

    Article  CAS  Google Scholar 

  14. Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113(1):238–46.

    Article  CAS  Google Scholar 

  15. Wang Y, Inger M, Jiang H, Tenenbaum H, Glogauer M. CD109 plays a role in osteoclastogenesis. PLoS One. 2013;8(4):e61213.

    Article  CAS  Google Scholar 

  16. Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010;60(11):735–43.

    Article  Google Scholar 

  17. Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, et al. CD109 expression levels in malignant melanoma. J Dermatol Sci. 2010;57(2):140–2.

    Article  CAS  Google Scholar 

  18. Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci. 2008;99(10):1916–23.

    CAS  PubMed  Google Scholar 

  19. Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58(5):288–94.

    Article  Google Scholar 

Download references

Acknowledgments

This study was funded by the China National Natural Science Foundation (No. 81102029 and 81172047) and Liaoning National Natural Science Foundation (No. 2013021006).

Conflicts interests

None

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, No. 150 Haping Road, Harbin, 150040, Heilongjiang Province, China

    Ji Tao & Qingwei Li

  2. Department of Breast and Lymphoma Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, No. 150 Haping Road, Harbin, 150040, Heilongjiang Province, China

    Hongbin Li

  3. Department of Oncology, The 2nd Hospital Affiliated to Harbin Medical University, Harbin, 150086, China

    Yu Yang

Authors
  1. Ji Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongbin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qingwei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu Yang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tao, J., Li, H., Li, Q. et al. CD109 is a potential target for triple-negative breast cancer. Tumor Biol. 35, 12083–12090 (2014). https://doi.org/10.1007/s13277-014-2509-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2509-5

Keywords

Search

Navigation